Summary
Boston Scientific Corporation (BSX) announced on May 28, 2025, the discontinuation of worldwide sales for its ACURATE neo2™ and ACURATE Prime™ Aortic Valve Systems. This strategic decision stems from recent regulatory discussions that have imposed significantly increased clinical and regulatory requirements for maintaining existing approvals and obtaining new ones globally. The company deemed the additional investments and resources necessary to meet these escalating demands to be prohibitive. Despite the anticipated financial impact from exiting these product lines, Boston Scientific currently expects to achieve its previously issued second quarter and full year 2025 sales and adjusted earnings per share guidance. However, the company is not reaffirming its GAAP EPS guidance for the same periods and plans to provide further details during its second quarter 2025 earnings call. Investors should monitor upcoming communications for a clearer picture of the financial ramifications and the company's updated outlook.
Key Highlights
- 1Discontinuation of worldwide sales for ACURATE neo2™ and ACURATE Prime™ Aortic Valve Systems.
- 2Decision driven by prohibitive increased global regulatory and clinical requirements.
- 3Company anticipates achieving previously stated Q2 and Full Year 2025 reported and organic sales guidance.
- 4Company expects to achieve previously stated Q2 and Full Year 2025 adjusted earnings per share guidance.
- 5GAAP EPS guidance for Q2 and Full Year 2025 is not being reaffirmed at this time.
- 6Additional information on financial impacts to be provided during the Q2 2025 earnings call.